Market closedNon-fractionalADR

BioLineRx/BLRX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About BioLineRx

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Ticker

BLRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

Headquarters

Modiin, Israel

Employees

79

BioLineRx Metrics

BasicAdvanced
$58M
Market cap
-
P/E ratio
-$0.76
EPS
1.54
Beta
-
Dividend rate
$58M
1.54
$2.53
$0.55
9.3
1.138
1.046
54.877
86.631
-519.43%
-81.75%
-188.40%
-127.94%
5.014
4.136
-30.32%

What the Analysts think about BioLineRx

Analyst Ratings

Majority rating from 1 analysts.
Buy

BioLineRx Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-8.82% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$6.8M
41.67%
Net income
-$600K
-95.65%
Profit margin
-8.82%
-96.93%

BioLineRx Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 9.09%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.15
-$0.30
-$0.30
-$0.15
-
Expected
-$0.17
-$0.13
-$0.26
-$0.17
-$0.29
Surprise
-11.76%
130.77%
15.38%
-9.09%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for BioLineRx stock?

BioLineRx (BLRX) has a market cap of $58M as of July 06, 2024.

What is the P/E ratio for BioLineRx stock?

The price to earnings (P/E) ratio for BioLineRx (BLRX) stock is 0 as of July 06, 2024.

Does BioLineRx stock pay dividends?

No, BioLineRx (BLRX) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next BioLineRx dividend payment date?

BioLineRx (BLRX) stock does not pay dividends to its shareholders.

What is the beta indicator for BioLineRx?

BioLineRx (BLRX) has a beta rating of 1.54. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell BioLineRx stock

Buy or sell BioLineRx stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing